title: [Management of malignant tumors of the thymus].
abstract: Twenty-eight patients with malignant tumors of the thymus were surgically treated during the 15-year period from 1969 to 1984. Twenty-six patients had far advanced disease when treatment was began. Of fifteen patients with malignant thymoma, the tumors were successfully removed in five patients by using the technique of combined resection of SVC. Of two patients with carcinoid, one is alive and another died two years after extended operation. Of two patients with malignant lymphoma, one with non Hodgkin's disease died three years after operation, and the other with Hodgkin's disease is alive with tumor bearing. It is important to distinguish malignant lymphoma from other types of thymic tumors, because chemo-radiotherapy is superior to surgical therapy. Of nine patients with germ cell tumor, two patients with seminoma have been well for 11 and 5 years. CDDP and radiotherapy were effective on their long survival. Three patients with embryonal carcinoma responded well to combined surgical and chemo-radiotherapy. But only one of them is alive with tumor free one year after operation. Prosthetic grafts were employed in 7 cases for replacement of the innominate and superior caval vein. Angiogram taken one month after operation disclosed the overall patency rate with 92% and the longest patent period confirmed was 4 years. Extended operation by using the prosthetic graft should be performed in the advanced cases to achieve a complete removal and to aim better prognosis for this kind of disease. In conclusion, aggressive surgical removal followed by radio-chemotherapy offers best cure of the malignant thymic tumor.
authors.forename: N
authors.initials: N
authors.lastname: Tubota
authors.forename: C
authors.initials: C
authors.lastname: Yamashita
authors.forename: N
authors.initials: N
authors.lastname: Ishii
authors.forename: K
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: R
authors.initials: R
authors.lastname: Aogauchi
authors.forename: S
authors.initials: S
authors.lastname: Yasuoka
authors.forename: K
authors.initials: K
authors.lastname: Nakamura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001807:Blood Vessel Prosthesis; D002276:Carcinoid Tumor / Q000601:surgery* / Q000628:therapy; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000601:surgery / Q000628:therapy; D005260:Female; D006689:Hodgkin Disease / Q000601:surgery; D006801:Humans; D008223:Lymphoma / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009373:Neoplasms, Germ Cell and Embryonal / Q000601:surgery* / Q000628:therapy; D013945:Thymoma / Q000601:surgery* / Q000628:therapy; D013953:Thymus Neoplasms / Q000601:surgery* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents